Arcturus Therapeutics Holdings (ARCT) Liabilities and Shareholders Equity (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $245.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 26.03% year-over-year to $245.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (down 22.78% YoY) and the FY2025 annual result came in at $271.1 million, down 21.19% from the prior year.
• Liabilities and Shareholders Equity retreated to $245.4 million in Q1 2026, from $271.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $470.9 million in Q1 2023 to a low of $245.4 million in Q1 2026.
• A 5-year average of $363.2 million and a median of $344.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slumped 32.43% — and 2023, when it surged 55.86%.
• Tracing ARCT's Liabilities and Shareholders Equity over 5 years: stood at $450.4 million in 2022, then slipped by 4.66% to $429.4 million in 2023, then dropped by 19.87% to $344.1 million in 2024, then slipped by 21.19% to $271.1 million in 2025, then fell by 9.49% to $245.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $245.4 million (Q1 2026), $271.1 million (Q4 2025), and $282.3 million (Q3 2025), per Business Quant data.